Cancer vaccines: a critical review on clinical impact

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Solid tumors develop resistance to immune surveillance through a process called immune editing.
• Immune editing involves the selection of cancer cells that are antigenically different and thus not recognized by the immune system.
• This phenomenon is analogous to the selective pressures exerted by chemotherapy and hormone therapy, driven by tumor clonal heterogeneity and molecular instability.

Purpose of the Study:

• To review common cancer vaccine strategies for solid tumors.
• To evaluate the evidence supporting the efficacy of these cancer vaccines.
• To address the challenges in comparing different vaccine approaches due to variations in technology, targets, and protocols.

Main Methods:

• Literature review of existing cancer vaccine strategies.
• Analysis of preclinical and clinical data on vaccine efficacy.
• Comparative assessment of different vaccine components (antigens, carriers, adjuvants) and administration schedules.

Main Results:

• Many cancer vaccines demonstrate efficacy in animal models but fail in clinical settings.
• Significant heterogeneity exists in vaccine development, including diverse technologies, antigens, carriers, adjuvants, and schedules.
• Direct comparison of different cancer vaccine strategies is difficult, leading to a confusing landscape.

Conclusions:

• Most cancer vaccines for solid tumors remain experimental and have negligible clinical utility.
• Regulatory approval is distant for the majority of current vaccine candidates.
• Further research and standardization are needed to overcome challenges in developing effective cancer vaccines.